Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FeedbackLSE:FDBK 3-Year EBITDA Growth Rate is 20.10% as of Nov. 2025, which is 38% above its 10-year median of 14.60. The stock has 4 warning signs investors should review. Among 525 Healthcare Providers & Services companies, Feedback ranks better than 66.48% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 20.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 25.40% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 6.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Feedback was 92.90% per year. The lowest was -415.50% per year. And the median was 14.60% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Feedback 3-Year EBITDA Growth Rate Related Terms
LSE:FDBK vs VEEV, BTSG, TEM: 3-Year EBITDA Growth Rate Comparison
For the Health Information Services subindustry, Feedback's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Feedback 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Feedback's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Feedback's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 20.10% mean?
Feedback (LSE:FDBK) has a 3-Year EBITDA Growth Rate of 20.10% as of Nov. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Feedback and its competitors. This is 38% above median its historical median of 14.60. According to the industry distribution chart, Feedback ranks #176 out of 525 companies in the Healthcare Providers & Services industry, placing it in the top 33.5%.
Is Feedback's 3-Year EBITDA Growth Rate too high?
Feedback's current 3-Year EBITDA Growth Rate of 20.10% is 38% above median its 10-year median of 14.60. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 9.90. Feedback's value of 20.10% is 103% above this industry median. Based on the distribution chart, Feedback ranks #176 out of 525 companies in the Healthcare Providers & Services industry, which is above the industry midpoint.
How does Feedback's 3-Year EBITDA Growth Rate compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Feedback ranks #176 out of 525 companies for 3-Year EBITDA Growth Rate. This puts Feedback in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 9.90. Feedback's value of 20.10% is 103% above this benchmark. While the company's 10-year median is 14.60 vs. the industry median of 9.90, Feedback has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 9.90, based on 525 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Feedback's current 3-Year EBITDA Growth Rate of 20.10% is 103% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Feedback and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 9.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Feedback's current 3-Year EBITDA Growth Rate is 20.10%, which is 38% above median its own 10-year median of 14.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Feedback stock overvalued right now?
Based on GuruFocus' analysis, Feedback (LSE:FDBK) is currently considered Possible Value Trap. The stock's GF Value™ is £0.14, compared to a current price of £0.07 — trading 51.1% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 20.10%, which is 38% above median its 10-year median of 14.60 and 103% above the Healthcare Providers & Services industry median of 9.90. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Feedback (LSE:FDBK), the current 3-Year EBITDA Growth Rate is 20.10% as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Feedback PLC is a medical imaging software and tools company. It develops and markets imaging tools and software for clinical decision-making, and also techniques and improved workflow for medical practitioners engaged in research and in treating patients. Its operating segments include Medical Imaging and Feedback Medical Imaging India. Its products include Bleepa, a regulated communication platform for sharing clinical results and supporting multidisciplinary teamwork, and CareLocker, a patient-facing platform that provides access and control over diagnostic and clinical data.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:FDBK has been successfully added to your 
